Phase 1/2 study of Allogeneic mesenchymal stem cells therapy for the treatment of severe COVID-19 patients
Latest Information Update: 25 Aug 2021
At a glance
- Drugs Allogeneic mesenchymal stem cells therapy-Bonus BioGroup (Primary)
- Indications Adult respiratory distress syndrome
- Focus Therapeutic Use
- 25 Aug 2021 New trial record
- 22 Aug 2021 According to a Bonus BioGroup media release, allogeneic mesenchymal stem cells therapy has been seized upon as a potential solution for relieving overburdened hospital systems to help prevent the imposition of economically damaging measures such as general lockdowns or closures.
- 22 Aug 2021 According to a Bonus BioGroup media release, Despite these significant complicating factors, patients were released from the hospital after a median duration of one day following the MesenCure treatment.